ELIXIR
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Elixir Capital Names Varun Mehta As CFO
Oct 15 (Reuters) - Elixir Capital Ltd ELIX.BO:
NAMES VARUN MEHTA AS CHIEF FINANCIAL OFFICER
RADHIKA MEHTA RESIGNED AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nBSEc6DR1H
Further company coverage: ELIX.BO
(([email protected];;))
Oct 15 (Reuters) - Elixir Capital Ltd ELIX.BO:
NAMES VARUN MEHTA AS CHIEF FINANCIAL OFFICER
RADHIKA MEHTA RESIGNED AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nBSEc6DR1H
Further company coverage: ELIX.BO
(([email protected];;))
Rite Aid bankruptcy plan approved, cutting $2 bln in debt
Updates throughout
By Dietrich Knauth
NEW YORK, June 28 (Reuters) - A U.S. bankruptcy judge on Friday approved Rite Aid's restructuring plan, allowing the pharmacy chain to cut its debt by $2 billion and turn over control to a group of lenders.
U.S. Bankruptcy Judge Michael Kaplan approved Rite Aid's bankruptcy plan at a court hearing in Trenton, New Jersey, saying that the restructuring had saved the company from having to shut down and liquidate operations.
Before Kaplan's ruling, Rite Aid attorney Aparna Yenamandra told the judge that 28,000 jobs could be lost if the restructuring deal was not approved.
"If we can't get it done now, we're simply never going to get it done," Yenamandra said.
Rite Aid filed for Chapter 11 in October 2023, after reporting $750 million in losses and $24 billion in revenue for the past fiscal year.
Rite Aid used its bankruptcy to close hundreds of stores, sell its pharmacy benefit company Elixir, and negotiate settlements with its lenders, drug distribution partner McKesson and other creditors.
Rite Aid's restructuring will provide $47.5 million to junior creditors, including individuals and local governments that have sued the company allegedly contributing to the deadly U.S. opioid epidemic. Before it filed for bankruptcy, Rite Aid faced 1,600 opioid lawsuits, including one by the federal government alleging that the company ignored red flags when filling suspicious prescriptions for addictive opioid pain drugs.
Arik Preis, an attorney representing opioid creditors, said that 22,000 individuals who had filed personal injury opioid claims in the Rite Aid bankruptcy stood to receive between $250 and $500 each. The settlement payments, though modest, are a victory for opioid claimants because of Rite Aid's high debt and dire financial troubles, Preis said.
"It's pretty awful, but it could have been worse," Preis said. "That's the reality of this case."
Rite Aid reached settlements with 16 of the 17 states where it operates, which resolved those states' opioid claims. Kaplan overruled an objection by Maryland, saying that the state could not hold up Rite Aid's bankruptcy so that it could continue an investigation into Rite Aid's opioid sales.
Rite Aid, which had over 2,000 stores when it filed for bankruptcy in October, will emerge from bankruptcy with about 1,300 remaining locations.
The company plans to exit from bankruptcy in about a month, funded by $2.55 billion in financing provided by its lenders, Yenamandra said.
Rite Aid will use the time to fine tune some of the details in its bankruptcy deal, including a last-minute change spurred by the U.S. Supreme Court Thursday ruling in the Purdue Pharma bankruptcy , which sharply scaled back bankruptcy courts' ability to stop lawsuits against people and organizations that did not file for bankruptcy.
To comply with that ruling, Rite Aid will work to ensure that its own deal's legal protections for non-debtors, such as Rite Aid's lenders and CEO, will have the consent of anyone who has a legal claim against those parties.
(Reporting by Dietrich Knauth
Editing by Chris Reese, Leslie Adler, Alexia Garamfalvi and Diane Craft)
(([email protected];))
Updates throughout
By Dietrich Knauth
NEW YORK, June 28 (Reuters) - A U.S. bankruptcy judge on Friday approved Rite Aid's restructuring plan, allowing the pharmacy chain to cut its debt by $2 billion and turn over control to a group of lenders.
U.S. Bankruptcy Judge Michael Kaplan approved Rite Aid's bankruptcy plan at a court hearing in Trenton, New Jersey, saying that the restructuring had saved the company from having to shut down and liquidate operations.
Before Kaplan's ruling, Rite Aid attorney Aparna Yenamandra told the judge that 28,000 jobs could be lost if the restructuring deal was not approved.
"If we can't get it done now, we're simply never going to get it done," Yenamandra said.
Rite Aid filed for Chapter 11 in October 2023, after reporting $750 million in losses and $24 billion in revenue for the past fiscal year.
Rite Aid used its bankruptcy to close hundreds of stores, sell its pharmacy benefit company Elixir, and negotiate settlements with its lenders, drug distribution partner McKesson and other creditors.
Rite Aid's restructuring will provide $47.5 million to junior creditors, including individuals and local governments that have sued the company allegedly contributing to the deadly U.S. opioid epidemic. Before it filed for bankruptcy, Rite Aid faced 1,600 opioid lawsuits, including one by the federal government alleging that the company ignored red flags when filling suspicious prescriptions for addictive opioid pain drugs.
Arik Preis, an attorney representing opioid creditors, said that 22,000 individuals who had filed personal injury opioid claims in the Rite Aid bankruptcy stood to receive between $250 and $500 each. The settlement payments, though modest, are a victory for opioid claimants because of Rite Aid's high debt and dire financial troubles, Preis said.
"It's pretty awful, but it could have been worse," Preis said. "That's the reality of this case."
Rite Aid reached settlements with 16 of the 17 states where it operates, which resolved those states' opioid claims. Kaplan overruled an objection by Maryland, saying that the state could not hold up Rite Aid's bankruptcy so that it could continue an investigation into Rite Aid's opioid sales.
Rite Aid, which had over 2,000 stores when it filed for bankruptcy in October, will emerge from bankruptcy with about 1,300 remaining locations.
The company plans to exit from bankruptcy in about a month, funded by $2.55 billion in financing provided by its lenders, Yenamandra said.
Rite Aid will use the time to fine tune some of the details in its bankruptcy deal, including a last-minute change spurred by the U.S. Supreme Court Thursday ruling in the Purdue Pharma bankruptcy , which sharply scaled back bankruptcy courts' ability to stop lawsuits against people and organizations that did not file for bankruptcy.
To comply with that ruling, Rite Aid will work to ensure that its own deal's legal protections for non-debtors, such as Rite Aid's lenders and CEO, will have the consent of anyone who has a legal claim against those parties.
(Reporting by Dietrich Knauth
Editing by Chris Reese, Leslie Adler, Alexia Garamfalvi and Diane Craft)
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Elixir Capital do?
Axis Capital Markets (India) Ltd is a company based in India that specializes in trading and investing in shares and securities.
Who are the competitors of Elixir Capital?
Elixir Capital major competitors are Arunis Abode, Sai Capital, Annvrridhhi Ventures, Yash Trading&Finance, Srestha Finvest, Real Touch, Mefcom Cap Mkt. Market Cap of Elixir Capital is ₹67 Crs. While the median market cap of its peers are ₹70 Crs.
Is Elixir Capital financially stable compared to its competitors?
Elixir Capital seems to be less financially stable compared to its competitors. Altman Z score of Elixir Capital is 3.11 and is ranked 5 out of its 8 competitors.
Does Elixir Capital pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Elixir Capital latest dividend payout ratio is 4.65% and 3yr average dividend payout ratio is 6.1%
How has Elixir Capital allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Elixir Capital balance sheet?
Balance sheet of Elixir Capital is strong. But short term working capital might become an issue for this company.
Is the profitablity of Elixir Capital improving?
The profit is oscillating. The profit of Elixir Capital is ₹12.64 Crs for TTM, ₹15.61 Crs for Mar 2024 and -₹2.44 Crs for Mar 2023.
Is the debt of Elixir Capital increasing or decreasing?
Yes, The net debt of Elixir Capital is increasing. Latest net debt of Elixir Capital is ₹20.41 Crs as of Mar-25. This is greater than Mar-24 when it was ₹4.38 Crs.
Is Elixir Capital stock expensive?
Yes, Elixir Capital is expensive. Latest PE of Elixir Capital is 7.16, while 3 year average PE is 5.12. Also latest EV/EBITDA of Elixir Capital is 4.36 while 3yr average is 3.54.
Has the share price of Elixir Capital grown faster than its competition?
Elixir Capital has given lower returns compared to its competitors. Elixir Capital has grown at ~22.75% over the last 6yrs while peers have grown at a median rate of 28.5%
Is the promoter bullish about Elixir Capital?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Elixir Capital is 71.29% and last quarter promoter holding is 71.29%.
Are mutual funds buying/selling Elixir Capital?
There is Insufficient data to gauge this.